Rottem Menachem, Elbirt Daniel, Sthoeger Zev
Division of Allergy Asthma and Immunology, HaEmek Medical Center Afula, Israel.
Harefuah. 2005 Aug;144(8):547-53, 599, 598.
Chronic idiopathic urticaria (CIU) is a common and frustrating disorder defined as a regular recurrence of hives for a period of more than 6 weeks, and has a major impact on patients' daily quality of life--H1 receptor antagonists are considered to be particularly effective in reducing pruritus, and are recommended as first-line treatment in patients with CIU. However, the efficacy of the treatment is insufficient.
To evaluate the efficacy of desloratadine in CIU in Israeli patients.
An open label multicenter study in 10 centers in Israel. Upon completion of 3-14 days screening for eligibility, eligible patients were given desloratadine 5 mg for 4 weeks. The DLQI questionnaire and the severity of CIU were assessed at baseline and each week for 28 days.
One hundred and four patients aged 19 to 85 years (mean +/- SD 45.6 +/- 15.6) who suffered from moderate CIU, despite previous treatment with anti-histamine agents, were selected and treated with desloratadine 5 mg daily for 28 days. There was significant improvement for dermatologic quality of life in each of 10 parameters and in work productivity, and significant decrease in CIU symptoms and signs including the number and size of hives. In the overall evaluation of treatment 51% of patients reported complete or marked relief and 20% had no relief. Adverse events were reported as mild in 10 patients and moderate to severe in 2 patients who discontinued the study due to headache.
Desloratadine can be successfully used in the treatment of CIU.
慢性特发性荨麻疹（CIU）是一种常见且令人困扰的疾病，定义为风疹块定期复发超过6周，对患者的日常生活质量有重大影响。H1受体拮抗剂被认为在减轻瘙痒方面特别有效，被推荐作为CIU患者的一线治疗药物。然而，治疗效果并不理想。
评估地氯雷他定对以色列CIU患者的疗效。
在以色列10个中心进行的一项开放标签多中心研究。在完成3 - 14天的入选筛查后，符合条件的患者给予5毫克地氯雷他定，持续4周。在基线时以及之后的28天内每周评估皮肤病生活质量指数（DLQI）问卷和CIU的严重程度。
选择了104名年龄在19至85岁（平均±标准差45.6±15.6）的中度CIU患者，尽管他们之前接受过抗组胺药治疗，给予他们每日5毫克地氯雷他定治疗28天。10个参数中的每一个以及工作效率方面的皮肤病生活质量都有显著改善，CIU的症状和体征包括风疹块的数量和大小都有显著减少。在总体治疗评估中，51% 的患者报告完全或明显缓解，20% 的患者没有缓解。有10名患者报告不良事件为轻度，2名因头痛而停止研究的患者报告为中度至重度。
地氯雷他定可成功用于CIU的治疗。
